ciglitazone has been researched along with Cancer of Pituitary in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogazzi, F | 1 |
| Ultimieri, F | 1 |
| Raggi, F | 1 |
| Russo, D | 1 |
| Vanacore, R | 1 |
| Guida, C | 1 |
| Viacava, P | 1 |
| Cecchetti, D | 1 |
| Acerbi, G | 1 |
| Brogioni, S | 1 |
| Cosci, C | 1 |
| Gasperi, M | 1 |
| Bartalena, L | 1 |
| Martino, E | 1 |
1 other study available for ciglitazone and Cancer of Pituitary
| Article | Year |
|---|---|
PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.
Topics: Adenoma; Animals; Annexin A5; Apoptosis; Cell Line; DNA Fragmentation; Female; Gene Expression; Huma | 2004 |